SDC1 and Miyoshi myopathy: Finally, to determine the effect of NNU219 on cells isolated from patients with MM, CD138+ cells were purified from BM aspiration of 5 MM patients who were newly diagnosed (patients no. 2, 3 and 4) or exposed to multiple therapeutic protocols (patients no. 1 and 5 had previously received bortezomib, dexamethasone, or lenalidomide) and were treated with NNU219 for 24 h.